Now some researchers are hopeful that nanotechnology will eventually make it possible to deliver anti-vascular endothelial growth factor treatments to the back of the eye in drops, rather than injections, to stop blood vessel growth.
Experts have long recognized that the number of deaths from Alzheimer’s disease (AD) tends to be underreported. Now a new study published in Neurology attempts to quantify that under-reporting and projects the AD mortality rate to be five to six times higher than official estimates, suggesting that AD may be responsible for more than 500,000 annual deaths in the United States.
BrightFocus-funded Dr. Maya Koronyo-Hamaoui is the senior author on a groundbreaking publication that reported the ACE protein, which can increase blood pressure to dangerous levels in the body’s blood stream, can actually help to clear beta-amyloid in the brain by stimulating the immune system.
No treatments have yet been found to halt or reverse the progress of Alzheimer's disease. Now, a protein discovered 25 years ago in the research lab of Paul Lombroso, MD, the Elizabeth Mears and House Jameson Professor in the Child Study Center at Yale, may offer new hope.
Scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Researchers have implicated a mutant form of a protein called myocilin as a possible root cause of this increased eye pressure.
Scientists at Washington University School of Medicine in St. Louis have identified variations in a gene that double a person’s risk of developing Alzheimer’s disease later in life. Their research is published online in the journal Nature.
Researchers found that they could reduce beta-amyloid when their drug was added to cultured brain cells and when injected directly into the brains of mice designed to show features of Alzheimer’s disease.
December 6, 2013
Donate to Cure Brain and Eye Diseases
Help end Alzheimer's, Macular Degeneration, and Glaucoma